Abstract
Purpose
Inflammation may play a role in the development and progression of many cancers, including prostate cancer. We sought to test whether histological inflammation within prostate cancer was associated with more aggressive disease.
Methods
The slides of prostatectomy specimens were reviewed by a board-certified pathologist on 287 men from a Veterans Affairs Medical Center treated with radical prostatectomy from 1992 to 2004. The area with the greatest tumor burden was scored in a blinded manner for the degree of inflammation: absent, mild, or marked. We used logistic and Cox proportional hazards regression analysis to examine whether categorically coded inflammation score was associated with adverse pathology and biochemical progression, respectively.
Results
No inflammation was found in 49 men (17 %), while 153 (53 %) and 85 (30 %) had mild and marked inflammation. During a median follow-up of 77 months, biochemical recurrence occurred among 126 (44 %) men. On multivariate analysis, more inflammation was associated with greater risk of positive margins, capsular penetration, and seminal vesicle invasion (all p < 0.05). Marked inflammation was associated with increased PSA recurrence risk when adjusting for preoperative features only (HR 2.08, 95 % CI 1.02–4.24), but not after adjusting for pathologic features.
Conclusions
Inflammation within prostate cancer was associated with more advanced disease, although it is unclear whether aggressive disease caused increased inflammation or inflammation caused aggressive disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dennis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60(1):78–83
Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172(5 Pt 2):S6–S11 discussion S11-12
Haverkamp J, Charbonneau B, Ratliff TL (2008) Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem 103(5):1344–1353
Mahmud SM, Franco EL, Aprikian AG (2010) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 127(7):1680–1691
Jafari S, Etminan M, Afshar K (2009) Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J 3(4):323–330
Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99(8):608–615
Mahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG (2006) Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 15(2):158–164
Habel LA, Zhao W, Stanford JL (2002) Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 13(5):427–434
Leitzmann MF, Stampfer MJ, Ma J et al (2002) Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1):1108–1111
Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5(2):138–146
Sun J, Turner A, Xu J, Gronberg H, Isaacs W (2007) Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 25(3):250–259
Davidsson S, Fiorentino M, Andren O et al (2011) Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 20(10):2280–2287
Zhang W, Sesterhenn IA, Connelly RR, Mostofi FK, Moul JW (2000) Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. J Urol 163(1):131–136
Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J (1997) Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 157(4):1301–1303
Irani J, Goujon JM, Ragni E et al (1999) High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist multi center study group. Urology 54(3):467–472
McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA (2004) The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 91(3):541–543
Nonomura N, Takayama H, Nakayama M et al (2011) Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int 107(12):1918–1922
Higano CS, Schellhammer PF, Small EJ et al (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16):3670–3679
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW (2006) Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176(4 Pt 1):1404–1408
Acknowledgment
The study was supported by the Department of Veterans Affairs, the Department of Defense, Prostate Cancer Research Program (SJF), and the American Urological Association Foundation/Astellas Rising Star in Urology Award (SJF). Views and opinions of, and endorsements by the author(s) do not reflect those of the US Army or the Department of Defense.
Conflict of interest
No conflict of interest exists for any of the authors.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Klink, J.C., Bañez, L.L., Gerber, L. et al. Intratumoral inflammation is associated with more aggressive prostate cancer. World J Urol 31, 1497–1503 (2013). https://doi.org/10.1007/s00345-013-1065-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-013-1065-8